Product Information
Registration Status: ActiveMITOMYCIN-C KYOWA FOR INJECTION 2mg/VIAL is approved to be sold in Singapore with effective from 1988-08-06. It is marketed by KYOWA KIRIN ASIA PACIFIC PTE LTD, with the registration number of SIN01721P.
This product contains Mitomycin 2mg/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS, INTRA-ARTERIAL, INTRAVESICAL use.
This product is manufactured by KYOWA HAKKO KIRIN CO. in JAPAN.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. [PubChem]
Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
Mechanism of Action
Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.
Pharmacokinetics
- Absorption
- Erratic.
- Distribution
- Metabolism
- Primarily hepatic, some in various other tissues.
- Elimination
Toxicity
Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Active Ingredient/Synonyms
7-Amino-9alpha-methoxymitosane | Ametycine | Mitamycin | Mitocin-C | Mitomycin | Mitomycin C | MMC | Mitomycin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.